Kalypsys gains $100M in third round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Kalypsys
|
$100M
|
Tavistock Life Sciences |
Kalypsys' pipeline includes KD3010 for metabolic disorders. |
|
Concert Pharmaceuticals
|
$48M
|
Flagship Ventures |
The company will explore its technology and advance its pipeline into clinical evaluation. |
|
Elixir Pharmaceuticals
|
$46M
|
MPM Capital |
The money will be used to support its program for Glufast, a small molecule for the treatment of Type 2 diabetes, and other programs |
|
Xanthus Pharmaceuticals
|
$25M
|
Oxford Bioscience Partners, HealthCare Ventures, GeneChem, GIMV, Hambrecht & Quist Capital Management, Still River Fund, Neomed, Kestrel Ventures, CDP Capital, CDIB BioScience Ventures, and Yasuda |
Xanthus has five oncology therapies in its pipeline. |
|
Cara Therapeutics
|
$19M
|
MVM Life Science Partners and Alta Biopharma Partners |
The money will get its next two drugs into the clinic. |
|
Alimera Sciences
|
$15.9M
|
BA Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners and Venrock Associates, and several individual investors |
The additional resources will be used to further develop Medidur, Alimera Sciences' Phase III-stage treatment for diabetic macular edema (DME). |
|
Cardioxyl Pharmaceuticals
|
$14.5M
|
The Aurora Funds and New Enterprise Associates |
Much of the money will go to developing its nitroxyl donor program for the treatment of acute decompensated heart failure. |
|
Quinnova Pharmaceuticals
|
$13.6M
|
Thomas, McNerney & Partners, H.I.G. Ventures and an investor syndicate led by Omnivest |
The company will accelerate the development of its pipeline and introduce its first dermatological prescription drug products to market in 2007. |
|
AmpliMed
|
$8.5M
|
Insight Ventures |
The new funds will be used to complete Phase I and II trials of Amplimexon. |
|
Aushon BioSystems
|
$7.78M
|
North Bridge Venture Partners |
Aushon provides microarray-based tools, instrumentation and services. |